Form 4 for VKTX Viking Therapeutics, Inc.
Accepted 2026-01-05 00:00:00 ET · period of report 2026-01-02 · accession 0001193125-26-003109 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-01-05 | 2026-01-02 | VKTX | FOEHR MATTHEW W | Dir | A - Grant | $0.00 | +3,150 | 135.2K | +2% | $0 |
| D | 2026-01-05 | 2026-01-02 | VKTX | FOEHR MATTHEW W | Dir | M - OptEx | $3.33 | +16.0K | 148.0K | +12% | +$53.3K |
| D | 2026-01-05 | 2026-01-02 | VKTX | FOEHR MATTHEW W | Dir | S - Sale+OE | $35.11 | -16.0K | 132.0K | -11% | -$561.8K |
| D | 2026-01-05 | 2026-01-02 | VKTX | FOEHR MATTHEW W | Dir | M - OptEx | $0.00 | -16.0K | 0 | -100% | $0 |
| D | 2026-01-05 | 2026-01-02 | VKTX | FOEHR MATTHEW W | Dir | A - Grant | $0.00 | +20.4K | 20.4K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock, par value $0.00001 per share | 2026-01-02 | A | A | 3,150 | $0.00 | 135,186 | D | — | — | (F2) Represents a restricted stock unit award ("RSU") of common stock under the Issuer's 2024 Equity Incentive Plan. All shares subject to the RSU shall vest on the one year anniversary of the grant date of the award. |
| 2 | Common | Common Stock, par value $0.00001 per share | 2026-01-02 | M | A | 16,000 | $3.33 | 148,036 | D | — | — | |
| 3 | Common | Common Stock, par value $0.00001 per share | 2026-01-02 | S | D | 16,000 | $35.11 | 132,036 | D | — | — | (F1) The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $34.94 to $35.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
| 4 | Derivative | Stock Option (Right to Buy) | 2026-01-02 | M | D | 16,000 | $0.00 | 0 | D | $3.33 · 2017-01-04 to 2026-01-04 | 16,000 Common Stock | |
| 5 | Derivative | Stock Option (Right to Buy) | 2026-01-02 | A | A | 20,400 | $0.00 | 20,400 | D | $35.42 · 2027-01-02 to 2036-01-02 | 20,400 Common Stock |